Company also achieves milestone of more than 400 patients treated with the DS1000 System
ST. LOUIS PARK, Minn.--(BUSINESS WIRE)--NeoChord, Inc., today announced the appointment of Alex Jonkers as Vice President of Commercial Sales in Europe.
“We are excited to fill this critical role in the organization with such high caliber talent as Alex. He has led the successful adoption of several transformational products throughout his career in the structural heart space and is exactly the leader NeoChord needs as we expand our commercial footprint with the DS1000 System in Europe,” said David Chung, President and CEO of NeoChord.
Most recently, Jonkers was with Medtronic, Inc., leading a large commercial organization responsible for catheter-based therapies and surgical heart valves across the EMEA region. Prior to Medtronic, he was with CoreValve, Inc., serving in a clinical and sales leadership capacity and a key member of the team that directed the successful integration of CoreValve into the Medtronic organization upon acquisition.
“I am thrilled to be a part of the team at NeoChord and am excited to bring this innovative procedure option to more patients,” stated Jonkers. “As an off-bypass device, I see tremendous potential for consideration of NeoChord’s technology as an early treatment option for patients suffering from degenerative mitral valve regurgitation (DMR).”
Additionally, the company today announced the treatment of more than 400 patients with the DS1000 System.
“Achieving this milestone is a significant endorsement of the technology and therapy from the cardiovascular community,” said Chung.
About NeoChord, Inc.
Based in St. Louis Park, Minn., NeoChord, Inc. is a privately held medical technology company leading the advancement of minimally invasive repair for degenerative mitral regurgitation (DMR). DMR is a progressive disease that can result in atrial fibrillation, congestive heart failure, and death when left untreated. NeoChord received CE market clearance in December 2012 for the DS1000 System to treat DMR without the use of cardiopulmonary bypass. For more information, visit: www.NeoChord.com.
The NeoChord DS1000 System is CE marked and approved for sale in Europe.
CAUTION: Investigational Device Limited by Federal (United States) Law to Investigational Use
Contacts
NeoChord, Inc.
Bruce Van Deman, 952-698-7812
bvandeman@neochord.com
ST. LOUIS PARK, Minn.--(BUSINESS WIRE)--NeoChord, Inc., today announced the appointment of Alex Jonkers as Vice President of Commercial Sales in Europe.
“We are excited to fill this critical role in the organization with such high caliber talent as Alex. He has led the successful adoption of several transformational products throughout his career in the structural heart space and is exactly the leader NeoChord needs as we expand our commercial footprint with the DS1000 System in Europe,” said David Chung, President and CEO of NeoChord.
Most recently, Jonkers was with Medtronic, Inc., leading a large commercial organization responsible for catheter-based therapies and surgical heart valves across the EMEA region. Prior to Medtronic, he was with CoreValve, Inc., serving in a clinical and sales leadership capacity and a key member of the team that directed the successful integration of CoreValve into the Medtronic organization upon acquisition.
“I am thrilled to be a part of the team at NeoChord and am excited to bring this innovative procedure option to more patients,” stated Jonkers. “As an off-bypass device, I see tremendous potential for consideration of NeoChord’s technology as an early treatment option for patients suffering from degenerative mitral valve regurgitation (DMR).”
Additionally, the company today announced the treatment of more than 400 patients with the DS1000 System.
“Achieving this milestone is a significant endorsement of the technology and therapy from the cardiovascular community,” said Chung.
About NeoChord, Inc.
Based in St. Louis Park, Minn., NeoChord, Inc. is a privately held medical technology company leading the advancement of minimally invasive repair for degenerative mitral regurgitation (DMR). DMR is a progressive disease that can result in atrial fibrillation, congestive heart failure, and death when left untreated. NeoChord received CE market clearance in December 2012 for the DS1000 System to treat DMR without the use of cardiopulmonary bypass. For more information, visit: www.NeoChord.com.
The NeoChord DS1000 System is CE marked and approved for sale in Europe.
CAUTION: Investigational Device Limited by Federal (United States) Law to Investigational Use
Contacts
NeoChord, Inc.
Bruce Van Deman, 952-698-7812
bvandeman@neochord.com
